Cardiovascular Systems to Webcast Fiscal 2012 Second-Quarter Earnings Conference Call Tuesday, February 7
January 30 2012 - 1:08PM
Business Wire
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a
live webcast of its fiscal 2012 second-quarter conference call on
Tuesday, February 7, 2012, at 3:45 p.m. CT (4:45 p.m. ET). David L.
Martin, president and chief executive officer, and Laurence L.
Betterley, chief financial officer, will discuss the company’s
results for its fiscal second-quarter ended December 31, 2011, and
its financial outlook. The company will issue a post-market
earnings release on February 7.
To access the live webcast, go to the investor information
section of the company’s website, www.csi360.com, on the day of the
conference call and click on the webcast icon. A webcast replay
will be available beginning at 7 p.m. CT the same day.
To participate in the conference call, dial (888) 680-0860 and
enter 50105170. Please dial in at least 10 minutes prior to the
call. To pre-register for the call, log on to the following
website:
https://www.theconferencingservice.com/prereg/key.process?key=PMQCKQGEL.
When joining the call, pre-registered participants can enter their
PIN code, and other participants can press *0 to reach the
operator, or wait on the line for operator assistance.
If you do not have access to the Internet and want to listen to
an audio replay of the conference call, dial (888) 286-8010 and
enter access number 28270965. The audio replay will be available
beginning at 8 p.m. CT on Tuesday, February 7, 2012, through 6 p.m.
CT on Friday, February 10, 2012.
About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a
medical device company focused on developing and commercializing
innovative solutions for treating vascular and coronary disease.
The company’s Stealth 360°™, Diamondback 360® and Predator 360® PAD
Systems treat calcified and fibrotic plaque in arterial vessels
throughout the leg in a few minutes of treatment time, and address
many of the limitations associated with existing surgical, catheter
and pharmacological treatment alternatives. The U.S. FDA granted
510(k) clearance for the use of the Diamondback 360° in August 2007
and for the Stealth 360° in March 2011. To date, more than 59,000
PAD procedures have been performed using the Diamondback 360° and
Stealth 360° in leading institutions across the United States.
CSI has also commenced its ORBIT II Investigational Device
Exemption clinical trial to evaluate the safety and effectiveness
of its orbital technology in treating coronary arteries. The
coronary system is limited by federal law to investigational use
and is currently not commercially available in the United
States.
For more information, visit the company’s website at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024